• Diagnostic Clues Found for PAH
    Dr Talat Nasim

News & Views

Diagnostic Clues Found for PAH

Mar 25 2019

Researchers at the University of Bradford have identified a biomarker that could be used to provide earlier diagnosis for Pulmonary arterial hypertension (PAH), a life limiting condition affecting around 6,500 people in the UK. Caused by a narrowing of the arteries supplying blood to the lungs and leading to possible heart failure, PAH can occur spontaneously at any age.

Led by Dr Talat Nasim, in Bradford’s School of Pharmacy and Medical Sciences and including researchers from the University of Cambridge (UK), Kings College London (UK), University of Dhaka (Bangladesh), Centre for Health Agricultural and Socio-economic Advancements (CHASA, Bangladesh) and Hacettepe University (Turkey), the study* builds on earlier research to investigate the genetic causes of PAH – in particular the mechanism of one faulty gene known as BMPR-II, which was first identified nearly two decades ago.
Dr Nasim explained: “We wanted to find out why the cells are not dying, but instead were building up inside the wall of the pulmonary arteries. To do this, we needed to identify and investigate the proteins that are influenced by this gene.”

The team discovered that the faulty BMPR-II gene affected one particular protein called Bcl-x. This, in turn, is responsible for making two different proteins, one of which increases cell apoptosis and the other one reduces it. These two work in balance in the body to regulate cell death. If BMPR-II is faulty, however, the protein for reducing cell apoptosis is increased – preventing cell death from occurring. “This protein can be used as a biomarker for accurately identifying PAH in patients,” said Dr Nasim. “This could help us diagnose PAH at an earlier stage, possibly leading to better treatment options for patients. We can also make other services available, such as genetic counselling, to help patients understand the disease and to identify those at risk of developing it.”

Dr Nasim’s team has filed a patent for the biomarker and is now investigating whether it could also be a target for new drugs. A number of promising compounds are currently being developed and tested.

*Published in Human Molecular Genetics

Digital Edition

ILM 49.5 July

July 2024

Chromatography Articles - Understanding PFAS: Analysis and Implications Mass Spectrometry & Spectroscopy Articles - MS detection of Alzheimer’s blood-based biomarkers LIMS - Essent...

View all digital editions


ADLM 2024

Jul 28 2024 San Diego, CA USA

InaLab 2024

Jul 30 2024 Jakarta, Indonesia


Jul 31 2024 Chengdu, China

ACS National Meeting - Fall 2024

Aug 18 2024 Denver, CO, USA


Aug 25 2024 Copenhagen, Denmark

View all events